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Medicare beneficiaries aged ≥ 65 years, diagnosed with depression, and no history of 
falls/fractures in 2007 (Baseline Period). Cases were identified as patients with inci-
dent fractures following the baseline period. For each case, 4 age and sex-matched 
controls were selected using incidence density sampling. The primary outcome 
was an inpatient or outpatient claim for fractures, between January 1, 2008 and 
December 31, 2010. Anticholinergic exposure was defined using Anticholinergic 
Drug Scale (ADS). Prescription of level 2/3 anticholinergic medications 30 days pre-
ceding the event date formed the primary exposure. Conditional logistic regression 
model stratified on matched case-control sets was performed to assess the fracture 
risk, after controlling for other risk factors of the outcome. RESULTS: The study 
sample included 43,402 cases of fractures and 173,608 matched controls (Incidence 
Density 1:4). After adjusting for other risk factors, there was no difference in risk 
with high-level anticholinergic use compared to non-use (Relative Risk, RR 1.02; 95% 
Confidence Interval [CI], 1.00-1.04). The findings remained consistent across levels 
of anticholinergic potency (Level 2, RR 1.01, 95% CI, 0.98-1.06; Level 3, 95% CI, 1.03, 
0.99-1.07). CONCLUSIONS: Use of anticholinergic medications was not associated 
with a higher risk of fractures compared to no use among elderly residents with 
depression. Given their safety concerns, there is a need to further evaluate other 
adverse outcomes associated with anticholinergics in the elderly.
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OBJECTIVES: This study compares the risks of side effects [SE] associated with a 
broad of range of typical and atypical antipsychotics used to treat patients with 
schizophrenia. METHODS: Medical and pharmacy claims data from Humana from 
January 2007 to June 2013 were used to define episodes of antipsychotic drug therapy 
for patients with schizophrenia. Episodes were screened for a minimum of 180 days 
of pre-episode and 360 days of post-episode data, and for the existence of study SEs 
prior to the episode index date. Study samples ranged from N= 97,481 for rhabdomy-
olysis (RM) to N= 99,017 acute urinary retention (AUR). Other SE for analysis included 
acute kidney injury (AKI), hypotension, pneumonia (PNA), acute coronary syndrome 
(ACS) or ischemic stroke/cerebral infarction, and ventricular cardiac arrhythmia 
(VCA). Logistic regression models were used to estimate the impact of alternative 
antipsychotics on the risk of an emergent SE in the year following the initiation 
of treatment. The logistic models controlled for patient demographics, treatment 
history, concomitant use of antidepressants, mood stabilizers and anticonvulsants, 
and diagnostic and drug use profiles in the prior 6 months. Haloperidol was used as 
the comparison drug. RESULTS: Perphenazine and ziprasidone reduced the risk of 
acute cardiovascular events relative to haloperidol. The risk of acute kidney injury 
was significantly increased in patients taking aripiprazole, olanzapine, quetiapine, 
risperidone and ziprasidone relative to haloperidol. The risk of hypotension was 
elevated in chlorpromazine and quetiapine patients and reduced in those using pali-
peridone, perphenazine and thiothixene. The risk of AUR was increased in patients 
using fluphenazine, but reduced in patients using aripiprazole, risperidone and 
thiothixene. The risk of RM was increased by the use of fluphenazine and quetia-
pine while the risk of pneumonia was elevated for patients using chlorpromazine, 
clozapine, paliperidone and quetiapine. CONCLUSIONS: The risk of side effects 
varies widely across antipsychotic medications.
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OBJECTIVES: This study compares the risks of side effects [SE] associated with a broad 
of range of atypical and typical antipsychotics used to treatment patients with bipolar 
disorder. METHODS: Medical and pharmacy claims data from Humana from January 
2007 to June 2013 were used to define episodes of antipsychotic drug therapy for 
patients with bipolar disorder. Episodes were screened for a minimum of 180 days of 
pre-episode and 360 days of post-episode data, and for the existence of study SEs prior 
to the episode index date. Study samples ranged from N= 147,658 for rhabdomyolysis 
[RM] to N= 150,084 acute urinary retention [AUR]. Other SE for analysis included acute 
kidney injury [AKI], hypotension, pneumonia (PNA), acute coronary syndrome (ACS) 
or ischemic stroke/cerebral infarction, ventricular (tachy) arrhythmia (VCA). Logistic 
regression models were used to estimate the impact of alternative antipsychotics on 
the risk of an emergent SE in the year following the initiation of treatment. The logistic 
models controlled for patient demographics, treatment history, concomitant use of 
antidepressants, mood stabilizers and anticonvulsants, diagnostic and drug use pro-
files in the prior 6 months. Haloperidol was used as the comparison drug. RESULTS: 
Aripiprazole, ziprasidone and risperidone did not differentiate relative to haliperidol. 
Only fluphenazine increases the risk of cardiovascular events relative to heliperidol. 
All other SE impacts related to specific antipsychotics were related to kidney disorders 
or pneumonia. Chlorpromazine increased the risk of acute kidney injury, hypoten-
sion, rhabdomyolysis and pneumonia. Clozapine increased the risk of pneumonia. 
Olanzapine increased the risk of AKI and pneumonia but significantly decreased the 
risk of AUR. Paliparidone also increased the risk of PNA and decreased the risk of 
AUR. Quetiapine increased the risk of AKI while perphenazine decreased the risk of 
hypotension and thiothixene decreased the risk of AUR. CONCLUSIONS: The risk of 
side effects varies widely across antipsychotic medications.
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OBJECTIVES: The epidemiological evidence of panic disorder (PD) is limited and 
little is known about the treatment for PD in the real clinical setting. The aim of 
this study was to determine the prevalence of PD, and to investigate concurrent 
diseases and prescriptions in patients with PD using a Japanese healthcare insur-
ance claims database. METHODS: This was a retrospective cohort study in patients 
having at least one diagnosis record of PD (ICD-10 code: F41.0), extracted from the 
MinaCare claims database (MinaCare Co. Ltd, Japan). The annual prevalence was 
estimated based on claims of fiscal years of 2011 and 2012 (Apr to Mar). The study 
cohort to investigate concurrent diseases and prescribed drugs consists of newly 
diagnosed patients, which was defined as patients with no diagnosis record of PD 
within 6 months prior to the 1st diagnosis of PD in the database. RESULTS: The 
estimated annual prevalence of PD was approximately 0.3%. Higher prevalence was 
observed in females in their 20s, 30s and 40s. In 2,100 newly diagnosed PD patients, 
the common diseases recorded concurrently at 1st PD diagnosis were insomnia, 
depression and neurosis. The predominant drugs prescribed at 1st PD diagnosis 
were SSRIs and benzodiazepines, as recommended in the current guideline as 1st 
line treatment; however, the proportion of patients prescribed both SSRIs together 
with benzodiazepines was less than 40%, and almost half of the patients were not 
prescribed SSRIs at 1st PD diagnosis. This prescription trend showed no remarkable 
change during the 6 months post-diagnosis period. CONCLUSIONS: The estimated 
prevalence including gender difference and age distribution were consistent with 
previous studies of PD. However, the prescription at 1st PD diagnosis suggests the 
existence of a gap between the real-world practices and the guideline recommen-
dation. Further investigation is needed to identify possible factors having impact 
on adequate treatment of PD.
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OBJECTIVES: The prevalence of co-occurring depression in chronic obstructive 
pulmonary disease (COPD) is as high as 40% and associated with substantial nega-
tive outcomes. Prior studies have shown that combined treatment with psycho-
therapy and antidepressants is superior to antidepressant treatment alone in 
reducing depressive symptoms and improving quality of life. However, popula-
tion based studies on the patterns of depression treatment among individuals 
with co-occurring COPD and depression are limited. We examined the patterns 
of depression treatment in various subgroups of individuals with co-occurring 
COPD and depression. METHODS: We used a retrospective, cross-sectional study 
design, pooling data from the 2009 and 2011 Medical Expenditure Panel Survey 
(MEPS). The analytical sample consisted of 886 individuals aged 21 years or older, 
diagnosed with COPD and depression. We classified depression treatment into 
three mutually exclusive categories: no depression treatment; antidepressants 
use only; and psychotherapy in conjunction with antidepressants. We conducted 
chi-squared tests and multinomial logistic regressions to examine patterns of 
depression treatment by socio-demographic, medical conditions and health status 
characteristics of this population. RESULTS: Overall, 18.5% of the study population 
reported no treatment for depression, 72% reported antidepressants use only and 
only 9.5% reported the use of psychotherapy in conjunction with antidepressants. 
Females were significantly more likely than males to receive psychotherapy and 
antidepressants for depression treatment (AOR= 2.41, 95% CI= 1.21, 4.81). Uninsured 
individuals were less likely than individuals with private insurance in receiv-
ing combined treatment (AOR= 0.25, 95% CI= 0.08, 0.84). Individuals with fair/poor 
perceived mental health status were more likely to receive combined treatment 
than individuals reporting excellent/ very good mental health status (AOR= 4.19, 
95% CI= 1.59, 11.05). Those with anxiety were significantly more likely to receive 
combined treatment (AOR= 3.21, 95% CI= 1.62, 6.37). CONCLUSIONS: Future stud-
ies need to identify the barriers to combined treatment of depression with psy-
chotherapy and antidepressants among various subgroups of individuals with 
co-occurring COPD and depression.
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OBJECTIVES: Few studies discuss the effectiveness and side effects of the use of 
antipsychotics in the pediatric population, despite the poor prognosis associated 
with the disorder, including high suicide risk. This study explores the efficacy of 
trialled antipsychotics for early-onset schizophrenia in order to determine which 
treatments are potentially efficacious in this population. METHODS: A systematic 
literature review was performed to identify trials conducted in children and ado-
lescents with schizophrenia that reported symptom control (efficacy) using the 
positive and negative syndrome scale (PANSS), a medical scale frequently used 
for assessing the schizophrenia symptom severity in trials. A Bayesian random 
effects network-meta-analysis was performed, synthesizing data for relevant out-
comes, including mean change from baseline in PANSS scores (including positive 
and negative subscales), weight gain and treatment discontinuation due to adverse 
events. RESULTS: Eleven studies were identified in the systematic review, and ten 
were included in the network meta-analysis. All treatments showed a greater reduc-
tion in PANSS scores at 6 weeks vs placebo; however, not all results were statisti-
cally significant. Haloperidol had the greatest reduction vs placebo; and treatment 
ranking probabilities suggested that haloperidol had the highest probability of being 
the best treatment in the network for reducing total PANSS scores. All treatments 
showed a trend of greater odds of discontinuing treatment due to adverse events vs 
placebo. However, pairwise comparisons were statistically non-significant. Nine out 
of thirteen treatments showed a trend of increased weight compared with placebo, 
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but no pairwise comparisons were statistically significant. CONCLUSIONS: The 
analysis demonstrates that many of the treatments are efficacious in controlling 
symptoms, although side effects resulting from treatment should be considered; 
weight gain is commonly observed, and treatment discontinuation due to adverse 
events is variable between studies. The lack of high-quality studies in this popula-
tion highlights a need for further research.
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OBJECTIVES: To assess relative efficacy and tolerability of vortioxetine versus other 
antidepressants in patients with major depressive disorder (MDD) who experience 
inadequate response after treatment with selective serotonin reuptake inhibitors 
(SSRIs) or serotonin–norepinephrine reuptake inhibitors (SNRIs). METHODS: A 
systematic literature review identified 27 switch studies, three of which (REVIVE, 
Kasper 2013 and STAR*D) contributed to the relevant network for quantitative 
assessment, based on remission rate and withdrawal rate due to adverse events 
(AEs). Switch treatments compared to vortioxetine in the analysis were agomel-
atine, sertraline, venlafaxine XR and bupropion SR, commonly used in clinical 
practice. Simple adjusted indirect comparisons using Bucher’s method were also 
conducted, in line with guidelines from EUnetHTA. RESULTS: Direct analysis of 
remission rates based on the REVIVE study showed vortioxetine had a signifi-
cantly higher remission rate (relative difference: -11.0% [95% CI: -19.4; -2.6]) than 
agomelatine. Indirect comparisons revealed that vortioxetine had numerically 
higher remission rates than sertraline (relative difference: -14.4%, [95% CI: -29.9; 
1.1]), venlafaxine (relative difference: -7.20%, [95% CI: -24.3; 9.9]), and bupropion 
(relative difference: -10.70%, [95% CI: -27.8; 6.4]). Rate of withdrawals due to AE 
was numerically lower with vortioxetine than agomelatine (relative difference: 
3.6%, [95% CI: -1.1; 8.3]). Indirect comparison showed that withdrawal rates due 
to AE were significantly lower for vortioxetine than sertraline (relative difference: 
12.1%, [95% CI: 3.1; 21.1]), venlafaxine (relative difference: 12.3%, [95% CI: 0.8; 23.8]), 
and bupropion (relative difference: 18.3%, [95% CI: 6.4; 30.1]). CONCLUSIONS: The 
evidence supporting treatment strategies for patients with MDD with inadequate 
response to SSRI or SNRI is limited. This study demonstrates that remission rates 
for vortioxetine are numerically higher than other antidepressants widely used 
in clinical practice. Vortioxetine is a well-tolerated treatment, showing statisti-
cally lower withdrawal rates due to AE in patients with MDD with an inadequate 
response to prior SSRI or SNRI monotherapy.
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OBJECTIVES: To assess the effects of the reformulation of OxyContin (ERO) with 
physicochemical abuse-deterrent properties that are intended to make tablets 
harder to crush, dissolve or chew on rates of abuse of ERO compared to other opioids 
using 6 national surveillance systems at 3 years after reformulation. METHODS: 
Data from 6 surveillance systems were examined: 1) National Poison Data System 
(NPDS), 2) RADARS Poison Center(PC) Program, 3) NAVIPPRO ASI-MV System assess-
ing individuals in substance abuse treatment, 4) RADARS Drug Diversion program 
using law enforcement officials’ surveillance,5) doctor-shopping using the IMS 
prescription database, and 6) Spontaneous adverse event reports of fatalities to 
the manufacturer. Changes in abuse rates were compared from the year before (Jul 
2009-Jun 2010) to 3 years after (January 2011 - June 2013) reformulation of ERO. The 
period from July to December 2010 was considered a transition period. Comparator 
opioid groups were: a) other extended-release opioid analgesic tablets and capsules 
(excluding ERO, methadone and transdermal patches) and b) immediate-release 
oxycodone (single-entity and combination products). RESULTS: Compared to the 
year prior to reformulation, there were large decreases in abuse rates of ERO in 
all 6 surveillance systems in the 3 years after ERO reformulation: 55% decrease 
(p< 0.001) in NPDS, 55% decrease (p< 0.001) in RADARS PC, 48% decrease (p< 0.001) in 
NAVIPPRO System assessing individuals in substance abuse treatment, 61% decrease 
(p< 0.001) in RADARS Drug Diversion program using law enforcement officials’ sur-
veillance, 50% decrease in doctor shopping rates for ERO nationally. Reductions 
for ERO were significantly greater than changes for the two comparator opioid 
groups. Spontaneously reported overdose fatalities reported to the manufacturer 
decreased 87% by the 3rdyear, while non-fatal ERO reports did not decrease post-
reformulation. CONCLUSIONS: These findings indicate that abuse of ERO declined 
after its reformulation and these declines have persisted through three years post-
reformulation. Additional follow-up is ongoing.
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OBJECTIVES: Despite different pharmacological strategies in the management of 
depression, many patients experience inadequate response to treatment in clinical 
practice. A systematic review was carried out to perform a qualitative assessment 
of studies examining different antidepressant monotherapies in patients with 
major depressive disorder (MDD), and an inadequate response to prior selective-
serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor 
(SNRI) therapy. METHODS: MEDLINE®, Embase®, Cochrane, CDSR, and PsychINFO® 
databases, and clinical trial registries were searched from January 1980 to 27 March 
2014. The review included trials in patients with MDD with inadequate response to 
SSRIs/SNRIs. Included studies underwent a two-stage screening process conducted 
by two independent reviewers, with discrepancies reconciled by a third independent 
reviewer. Data were extracted by a single reviewer with quality check performed by 
another, and multiple publications were linked. The quality of included studies was 
critically appraised based on recommendations from national guidelines. RESULTS: 
The database search retrieved 11 953 citations, of which 27 randomized controlled 
trials from 54 publications met the inclusion criteria. The switch interventions 
assessed included: SSRIs, SNRIs, and other non-SSRI/SNRI antidepressants such as 
monoamine oxidase inhibitors, tricyclic antidepressants, tetracyclic antidepres-
sants, with a few studies comparing different antidepressants in switch therapy. 
The evidence varied in terms of: type of treatment, study duration (ranging from 
2 weeks to 14 weeks), depression scale, sample size (< 100 to > 500 patients), prior 
therapy, and definition of inadequate response. Generally, the mean age of included 
patients was comparable (44 years to 48 years). Overall, few of the included studies 
were deemed to be of good quality. CONCLUSIONS: A comprehensive overview of 
switch studies assessing antidepressant monotherapies in prior SSRI/SNRI non-
responding patients found an overall low strength of evidence for studies evaluating 
these monotherapies. Limited clinical data have been retrieved but give the pos-
sibility to perform further quantitative evaluations.
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OBJECTIVES: Paroxetine has strong anticholinergic properties and may lead to 
adverse cognitive outcomes. This study compared paroxetine and other selective 
serotonin reuptake inhibitors (SSRIs) with respect to cognition among elderly nurs-
ing home residents with depression. METHODS: A propensity score-adjusted retro-
spective cohort study was conducted using data from Medicare Part D claims and 
Minimum Data Set (MDS) from 2007-2010. New users of paroxetine and other SSRIs 
were followed until they reached the end of the follow up period (1 year), switched 
to a different antidepressant class, used psychotherapy, had a gap or more than 15 
days in the use of index antidepressant class, whichever occurred earlier. Exposure 
to SSRIs formed the main independent variable. The main outcome variable was 
cognition and it was measured using the MDS Cognition Scale. Repeated measures 
mixed model was used to examine the effect of SSRIs use on cognition, with use of 
other SSRIs as the reference category. Other covariates in the final model included 
propensity scores and their interaction terms. RESULTS: The study cohort consisted 
of 1,081 elderly nursing home residents. Of these, 63 (5.83%) received paroxetine 
and 1,018 received other SSRIs (94.17%). After adjusting for propensity scores, the 
repeated measure mixed model did not find any statistically significant difference in 
cognition with the use of paroxetine (β = -0.25 [95% CI, -0.84, 0.35]) when compared 
to other SSRIs. Results from the sensitivity analysis were consistent with the main 
findings. CONCLUSIONS: This study did not find any significant effect of paroxetine 
on cognition when compared to other SSRIs in elderly nursing home residents with 
depression. Long term studies are needed to evaluate comparative safety profiles 
of SSRIs in this vulnerable population.
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OBJECTIVES: Women are diagnosed with depression twice as often as men. 
Concerning self-reported depression though, gender differences are not that dis-
tinct. Prescription of antidepressants (ADs) has increased considerably the past 
decades, especially for women. This study aimed to examine gender differences in 
self-reported depression and the relation to prescribed ADs and also in the prescrip-
tion of various types of ADs. METHODS: Data from the population-based cross-sec-
tional survey “Public Health in Sweden 2012” was used (n= 16,000 aged 18-84 years, 
response rate 49.3%). Symptoms of depression were measured with the Hospital 
Anxiety Depression Scale (HADS, cut-off score ≥ 8). Self-reported use of ADs two 
weeks prior to receiving the questionnaire was supplemented with prescription data 
(ATC-codes) from the national Swedish Prescribed Drug Register. RESULTS: Men and 
women reported depression to similar extent (men 12.3%, women 11.2%). However, 
women were more often prescribed ADs compared to men (men 3.7%, women 6.8%; 
p< 0.0001). Nine per cent of all women in the study population reported depression 
but had no AD treatment, 2.1% reporting depression and used ADs, and 4.7% used 
ADs but reported no depression. The corresponding figures for men were 10.8%, 1.5% 
and 2.2% (p< 0.0001). Selective serotonin reuptake inhibitors (SSRIs, N06AB) were the 
most commonly prescribed ADs for both men (74.8%) and women (79.2%). As for the 
SSRIs, no statistical significant gender difference was found for the tricyclic antide-
pressants (TCAs, N06AA; men 9.5%, women 6.7%). However, men were prescribed 
“Other ADs” (N06AX) significantly more often than women (men 43.3%, women 
29.2%; p< 0.005). CONCLUSIONS: Although women and men reported depression 
to similar extent, women were prescribed ADs almost twice as often as men. Also, 
women used ADs without being currently depressed more often than men. Further, 
men were prescribed “Other ADs” more frequently than women.
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